癌細胞特異糖鎖抗原による慢性関節リウマチ患者に対する感作療法

点击翻译按钮获取中文摘要

As reported by us, a new myeloid cell population with an oncofetal membrane marker, dimeric Lex (di-Lex ; III3FucV3FucnLc6) , was found in the epiphyseal bone marrow adjacent to the involved joints of patients with severe rheumatoid arthritis (RA) .Patients with RA recieved intradermal (id) injections of di-Lex incorporated in liposome or of high molecular weight glycoprotein, or tumor assosiated carbohydrate antigen (TCA) , containing the same carbohydrate epitope as di-Lex. The epiphyseal myeloid cells were reduced or sometimes eliminated during id injection. In random trials of id injection, observation under clinical and laboratory conditions showed improvement in 63% (17/27) of the patients treated for 6 months with appropriate doses of di-Lex (III3FucnLc4) , and in 72% (31/43) of those treated with an identical protocol for TCA.However, id injection with monomeric Lex had no effect.